Skip to Content


Active Substance: pegfilgrastim
Common Name: pegfilgrastim
ATC Code: L03AA13
Marketing Authorisation Holder: Amgen Europe B.V.
Active Substance: pegfilgrastim
Status: Withdrawn
Authorisation Date: 2015-04-13
Therapeutic Area: Neutropenia
Pharmacotherapeutic Group: Immunostimulants

Therapeutic Indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

The marketing authorisation for Ristempa has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.